The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients
Jin Su(First Affiliated Hospital of Guangzhou Medical University), Jianxing He(Southern Medical University), Guoxia Zhang(Southern Medical University), Qiaoyan Lian(First Affiliated Hospital of Guangzhou Medical University), Yuhang Cai(First Affiliated Hospital of Guangzhou Medical University), Changxuan You(Southern Medical University), Haiyue Liu(First Affiliated Hospital of Xiamen University), Ao Chen(BGI Group (China)), Kun Li(Southern Medical University), Yan-Xia Lin(Shenzhen University), Chunrong Ju(First Affiliated Hospital of Guangzhou Medical University), Zhixuan You(Guangzhou Medical University), Chunxi Li(Nanfang Hospital), Jian-bing Pan(Nanfang Hospital)
Cited by 9
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays
|Cell|2022|1.7k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467